Therapeutic effects and tolerability of fluvoxamine treatment in adolescents with dysthymia

Journal of Child and Adolescent Psychopharmacology

Volumn 10, Issue 1, 2000, Pages 9-18

  Rabe Jablonska, Jolanta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; LORAZEPAM;

ADOLESCENT; AGITATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTHYMIA; EXCITABILITY; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MALE; NAUSEA; RELAPSE; VOMITING;

EID: 0034102440     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2000.10.9     Document Type: Article

References (41)

1. Ambrosini P, Bianchi M, Rabinovitch H: Antidepressant treatment in children and adolescents. I. Affective disorders. J Am Acad Child Adolesc Psychiatry 32:1-6, 1993
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. (DSM-III). Washington, DC, American Psychiatric Association, 1980
3. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., revised. (DSM-III-R). Washington, DC, American Psychiatric Association, 1987
4. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, DC, American Psychiatric Association, 1994
5. Apter A, Ratzone G, Kong RA, Weizman A, Iancu I, Binder M, Ridlle MA: Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. J Am Acad Child Adolesc Pschiatry 33:342-348, 1994
6. Bakish D, La Pierre YD, Wienstein R, Klein J, Wiens A, Jones B, Horn E, Browne M, Gourget O, Blanchard A: Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder. J Clin Psychopharamcol 13:409-414, 1993
7. Boulos C, Kutcher S: Antidepressant use in adolescents. Bull Can Acad Child Psychiatry 1:52-56, 1992
8. Delalleau B, Alby JM, Cabane J, Ferreri M: Eficacy and safety of tianeptine in major depressive disorders and in dysthymia with somatic complaints: Double-blind study vs. fluoxetine [abstract]. Presented at the XIX CINP, Washington, DC, 1994
9. De Sousa MP: Amisulpride in dysthymia: Results of naturalistic study in general practice. Eur Psychiatry 11(suppl 3): 145-147, 1996
10. DeVane CL, Sallee FR: Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: A review of published experience. J Clin Psychiatry 57:55-66, 1996
11. Dunner DL, Hendrickson HE, Bea C, Budech CB: Venlafaxine in dysthymic disorder. J Clin Psychiatry 58:528-531, 1997
12. Emslie GJ, Kowatch R, Costello L, Travis G, Pierce L: Double-blind study of fluoxetine in depressed children and adolescents [abstract]. Presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New Orleans, 1995
13. Frank E, Prien RF, Jarret RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM: Conceptualization and rationale for consensus definitions of terms in major depressive disorder: Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851-855, 1991
14. Garrison CZ, Jackson KL, Marsteller F, Mc Keown R, Addy A: A longitudinal study of depressive symptomatology in young adolescents. J Am Acad Child Adolesc Psychiatry 29:581-585, 1990
15. Garrison CZ, Addy A, Jackson KL, Mc Keown R, Waller JL: The CES-D as a screen for depression and other psychiatric disorders in adolescents. J Am Acad Child Adolesc Psychiatry 30:636-641, 1991
16. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62, 1960
17. Hazell P, O'Connell D, Heathcoat D, Robertson J, Henry D: Efficacy of tricyclic drugs in treating child and adolescent depression: A motor analysis. Br Med J 10:897-901, 1995
18. Hellerstein DJ, Yanowitch P, Rosenthal J, Samstag LW, Maurer MAM, Kasch K, Burrows L, Poster BAM, Cantillon BSM, Winston A: A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry 150:1169-1175, 1993
19. Howland RH: General health, health care utilization, and medical comorbidity in dysthymia. Int J Psychiatry Med. 23:211-238, 1993
20. Keller MB: Dysthymia in clinical practice: Course, outcome and impact on the community. Acta Psychiatr Scand Suppl 383:24-34, 1994
21. Kessler RC, Mc Gonagle KZ, Zhao S, Nalson CB, Hughes M, Eshleman S, Wittchen H, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from National Comorbidity Survey. Arch Gen Psychiatry 51:8-19, 1994
22. Kocsis JH, Frances AJ, Voss C, Mann JJ, Sweeney J: Imipramine treatment for chronic depression. Arch Gen Psychiatry 45:252-257, 1988
23. Kocsis JH, Sutton BM, Frances A: Long-term follow-up of chronic depression treated with imipramine. J Clin Psychiatry 52:56-59, 1991
24. Kocis JH, Zisooks S, Davidson J, Shelton R, Yonkers K, Hellerstein DJ, Rosenbaum J, Halbreich U: Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am J Psychiatry 154:390-395, 1997
25. Kutcher S: Practitioner review: The pharmacotherapy of adolescent depression. J Child Psychol Psychiatry 38:755-767, 1997
26. Lecrubier Y, Boyer P, Turjanski S, Puech A, Aubin F, Rein W: Amisulpride versus imipramine and placebo in dysthymic patients. J Affect Disord 43:95-103, 1997
27. Meco G, Marini S, Marini L: Ritanserin in dysthymic disorders (DSM-III): A double-blind study vs. amitriptyline. Psychopharmacology 96(suppl):282, 1986
28. Ravindran AV, Bialik RJ, Lapierre YD: Therapeutic efficacy of specific serotonin reuptake inhibitors (SSRIs) in dysthymia. Can J Psychiatry 39:21-26, 1994
29. Regier DA, Boyd JH, Burke JD Jr, Rae DS, Myers JK, Kramer M, Robins LN, George LK, Karno M, Lockze BZ: One-month prevalence of mental disorders in the United States: Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 45:977-986, 1998
30. Riddle MA, Claghorn J, Gaffney G, Greist JH, Holland D, Landbloom R, McConville B, Pigott T, Pravetz M, Walkup JT, Yaryura-Tobias J, Houser VP: A controlled trial of fluvoxamine for OCD in children and adolescents. Biol Psychiatry 39:500-568, 1996
31. Roberts RE, Lewisohn PM, Seeley JR: Screening for adolescent depression: A comparison of depression scales. J Am Acad Child Adolesc Psychiatry 30:58-66, 1991
32. Ryan ND: The pharmacologic treatment of child and adolescent depression. J Clin Psychiatry North Am 5:29-40, 1992
33. Simeon JG, Dinicola VF, Ferguson HB, Copping W: Adolescent depression: A placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 14:791-795, 1990
34. Smeraldi E: Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study. J Affect Disord 48:47-56, 1998
35. Spitzer RL, Williams JBW, Gibbon M: Instruction Manual for the Structured Clinical Interview for DSM-III-R (SCID, 4/1/87 Revision). New York, Biometrics Research Division, New York State Psychiatric Institute, 1987
36. Spitzer RL, Williams JBW, Gibbon M: Instruction Manual for the Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II, 10, 15, 86). New York, Biometrics Research Division, New York State Psychiatric Institute, 1987
37. Spitzer RL, Williams JBW, Kroenke K, Linzer M, de Gruy FV, Hahn SR, Brody D, Johnson JG: Utility of a new procedure for diagnosing mental disorders in primary care: The PRIME-MD 1000 Study. JAMA 272:1478-1483, 1994
38. Strober M: The pharmacotherapy of depressive illness in adolescence. III. Diagnostic and conceptual issues in the study of tricyclic antidepressants. J Child Adolesc Psychopharmacology 2:23-29, 1992
39. Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J, Rosenbaum J, Harrison W: A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 53:777-784, 1996
40. Tierney E, Joshi PT, Llinas JF, Rosenberg LA, Riddle MA: Sertraline for major depression in children and adolescents: Preliminary clinical experience. J Child Adolesc Psychopharmacology 5:13-22, 1995
41. Weissman MM, Leaf PJ, Bruce ML, Florio L: The epidemiology of dysthymia in five communities: Rates, risks, co-morbidity and treatment. Am J Psychiatry 145:815-819, 1988